Anti-VEGF Utilization In US Shows Preference For Bevacizumab

Despite similar safety and efficacy profiles as ranibizumab in recent studies, bevacizumab appears to be the preferred anti-VEGF agent with regard to utilization in the United States, according to one presenter here.